Physician profile
Nancy Flategraff
NPI 1346776002
$1,415.16
in general payments reported to CMS, 2019-2025
17 companies · $94.49 in 2025
The $94.49 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $337 · 2022: $453 · 2023: $221 · 2024: $310 · 2025: $94.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $625.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $625.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $405.92 | 2021-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $217.47 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $175.42 | 2021-2023 | Farxiga |
| Pfizer INC. | $106.83 | 2023-2025 | |
| Amgen INC. | $89.48 | 2022-2025 | Repatha, Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $79.11 | 2021-2023 | |
| Lilly USA, LLC | $72.16 | 2022-2023 | Mounjaro |
| Otsuka America Pharmaceutical, INC. | $65.54 | 2022-2023 | Rexulti |
| Abbott Laboratories | $42.90 | 2021-2022 | |
| Vbi Vaccine (Delaware) INC. | $40.91 | 2022 | |
| Paratek Pharmaceuticals, INC. | $23.87 | 2022 | |
| Idorsia Pharmaceuticals US INC | $19.21 | 2022 | |
| Ironshore Pharmaceuticals INC. | $18.46 | 2023 | Jornay Pm |
| Corium, LLC | $15.34 | 2023 | Azstarys |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.28 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $14.08 | 2025 | Fanapt |
| Amarin Pharma, INC. | $13.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Flategraff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.